Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02524197 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee
A Phase 2 study, sponsored by Cara Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 81
- Enrollment target
NCT02524197 is a Phase 2 study that has completed, run by Cara Therapeutics. The registered enrollment target is 81 participants.
The verdict
NCT02524197, a Phase 2 study, has completed, sponsored by Cara Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 81 participants
- Enrollment target
Study Summary
To assess the safety and tolerability of orally-administered CR845 in patients with osteoarthritis (OA) of the hip or knee. The study drug is being tested to reduce OA pain, and will be taken twice a day for two weeks, with four different doses (strengths) being tested. From screening period to follow up examination, the study is expected to last for up to 38 days per participant.
Interventions
- DRUG CR845 0.25 mg
- DRUG CR845 0.50 mg
- DRUG CR845 1 mg
- DRUG CR845 5 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2015-08 |
| Est. Completion | 2016-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02524197
The ClinicalTrials.gov registry entry for NCT02524197 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 81 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cara Therapeutics, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which CR845 0.25 mg is the first listed.
NCT02524197 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02524197 about?
NCT02524197 is a clinical study titled "A Study of the Safety and Effectiveness of Orally Administered CR845 in Patients With Osteoarthritis of the Hip or Knee". To assess the safety and tolerability of orally-administered CR845 in patients with osteoarthritis (OA) of the hip or knee. The study drug is being tested to reduce OA pain, and will be taken twice a day for two weeks, with four different doses (strengths) being tested. From screening period to foll...
What is the current status of trial NCT02524197?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 81 participants. The study started on 2015-08. Estimated completion is 2016-01.
What interventions are being tested in trial NCT02524197?
The interventions under investigation include: CR845 0.25 mg (DRUG), CR845 0.50 mg (DRUG), CR845 1 mg (DRUG), CR845 5 mg (DRUG).
Who is sponsoring clinical trial NCT02524197?
This trial is sponsored by Cara Therapeutics, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.